At the end of the fourth quarter of 2023, these 31 funds held both WuXi AppTec and WuXi Biologics

Mondo Finance Updated on 2024-02-01

The turmoil over the proposed introduction of the Biosecurity Act in the United States continues to attract the attention of investors. On January 29, WuXi AppTec and WuXi Biologics continued to be hit hard, with WuXi AppTec falling to a limit** and WuXi Biologics significantly exceeding 6%. In the face of this situation, investors who hold these two ** votes will definitely feel pain.

WuXi AppTec and WuXi Biologics have always been heavy stocks favored by many **. **Investment is originally to save worry and effort, and for those investors who buy both ** tickets at the same time, it seems a little heart-wrenching.

Let's take a look at which ** held both WuXi AppTec and WuXi Biologics at the end of the fourth quarter of 2023.

1.BOCOM Sustainable Growth Theme Mix A: WuXi AppTec 1019%, WuXi Biologics 631%

2.Tianhong Hang Seng Shanghai-Shenzhen-Hong Kong Innovative Drugs Select 50 ETF: WuXi AppTec 962%, WuXi Biologics 71%

3.CEIBS Medical Innovation**a: WuXi AppTec961%, WuXi Biologics 686%

4.Wells Fargo Shanghai-Hong Kong-Shenzhen Innovative Pharmaceutical Industry ETF: WuXi AppTec 946%, WuXi Biologics 723%

5.Huatai Pineapple CSI Innovative Pharmaceutical Industry ETF: WuXi AppTec 943%, WuXi Biologics 718%

6.Cathay CSI Shanghai-Hong Kong-Shenzhen Innovative Pharmaceutical Industry ETF: WuXi AppTec 941%, WuXi Biologics 709%

7.Innovative drug ETF Shanghai-Hong Kong-Shenzhen: WuXi AppTec 94%, WuXi Biologics 722%

8.Dongcai Innovative Drug A: WuXi AppTec 908%, WuXi Biologics 694%

9.Da Mo Shanghai-Hong Kong-Shenzhen Select Blend A: WuXi AppTec 883%, WuXi Biologics 762%

10.BOCOM Rui and three-year holding period mixed: WuXi AppTec 882%, WuXi Biologics 663%

At the end of the fourth quarter of 2023, there were 31 companies that held both WuXi AppTec and WuXi Biologics. The average market capitalization of WuXi AppTec as a percentage of net value is 723%, while the average market capitalization to net value of WuXi Biologics is 533%。It can be seen that these ** are generally heavy on these two ** votes.

Let's take a look at the recent performances of these**.

These ** have not performed well recently, which should have a lot to do with the ** of the entire investment market.

In the face of such an emergency, it is estimated that the ** manager does not have a good way to deal with it for the time being. For the people, they need to make a rational choice according to their own situation.

Related Pages